A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

Official title:

A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01820312
• Other study ID #: 136191
• Status: Withdrawn
• Phase: Phase 2
• First received: March 21, 2013
• Last updated: August 5, 2016
• Start date: January 2013
• Est. completion date: July 2015

Study information

• Verified date: August 2016
• Source: University of Arkansas
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if low-dose radiation therapy and the chemotherapy drug paclitaxel is effective in treating head and neck cancer that has returned after treatment with standard radiation therapy alone, but cannot be removed by surgery. The overall total dose received of both the chemotherapy and radiation therapy will be less than that typically given as standard of care; however, the Food and Drug Administration (FDA) has not evaluated the safety and effectiveness of this combination therapy. In addition, this study will gather information about the effects of radiation therapy and chemotherapy on subject's overall quality of life.

Description:

This study will evaluate a combination therapy of paclitaxel and LDFRT. The paclitaxel will be commercially available drug product dispensed by a licensed pharmacist at UAMS. Radiotherapy will be delivered using either the TomoTherapy Treatment System (TomoTherapy, Inc.) or the Varian High Energy Linear Accelerator (Varian Medical Systems).

Subjects will undergo CT imaging (to include neck, chest, abdomen and pelvis) as part of the standard of care approximately 7 to 21 days prior to initiation of this therapy. Additional CT imaging will be done at UAMS approximately 3 months after completion of protocol therapy and every 3 months subsequently until progression or completion of the study whichever comes first. These CT imaging's will be obtained for recurrent tumor evaluation and determination of the presence or absence of distant metastasis, as part of the standard of care.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject 18 years of age and older, male or female, of all races and ethnicities.

2. Subject with prior histologically confirmed advanced squamous-cell carcinoma of the head and neck that failed prior traditional chemoradiotherapy with at least a 3-month disease-free interval from the completion of the initial curative treatment.

3. Recurrence must have been confirmed via biopsy.

4. Subject must have an ECOG performance status of 0, 1 or 2.

5. Has undergone CT imaging within 21 days prior to treatment as part of routine care.

6. Measurable disease by CT.

7. Subject deemed likely to survive for at least 6 months.

8. Subject is able and willing to provide written informed consent to participate in the study.

9. If the subject is a female of childbearing age, the subject should have a negative urine pregnancy test and be practicing strict birth control (estrogen-containing oral contraceptives or an intrauterine device) throughout the study and for 3 months after completion of protocol treatment. Women who have had a hysterectomy are exempt from these requirements. This is routine for any patient undergoing treatment.

10. History of laboratory criteria as specified below (within 21 days prior to enrollment) Hemoglobin = 9 g/dl Platelet count >100,000 per microliter CO2 (carbon dioxide): 22-32 meq/L Creatinine: < 1.5 mg/dL or eGFR>40 ml/min Serum bilirubin <1.6 mg/dl. White blood count > 3,000 per microliter or ANC > 1500 per microliter Serum calcium <10.5 mg/dl.

Exclusion Criteria:

1. The tumor is not clearly shown on diagnostic imaging studies

2. Subject is pregnant.

3. Subject with known allergies/hypersensitivity to paclitaxel.

4. Subjects with poor renal function as demonstrated by serum creatinine (>1.5 mg/dl) and EGFR <40 mL/min, which would preclude the using of image contrast agents.

5. Subject with a planned surgical procedure within the next 30 days.

6. Subject has distant metastasis (with the exception of single stable distant metastasis that does not decrease life expectancy to less than 6 months).

7. Subject is of childbearing potential and will not use adequate contraceptive protection.

8. Subject who is breastfeeding.

9. Subject of childbearing potential who has a positive (+) urine pregnancy test.

10. Subject has received treatment with an experimental drug or entered another clinical trial within the prior 30 days.

11. Subject has received radiotherapy to the head and neck region within the prior 3 months.

12. Subject is not willing or able to complete the visit requirements of this protocol.

13. Peripheral neuropathy of any etiology.

14. Any other condition that the PI feels will be an endangerment to the subject.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Radiation:
• Low-Dose Fractionated Radiation Therapy/Paclitaxel

Locations

Country	Name	City	State
United States	University of Arkansas for Medical Sciences	Little Rick	Arkansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response (OR)	Objective Response (OR). OR will be defined according to RECIST v1.1 criteria as either a complete or partial response. OR will be determined in each subject 3 months following therapy using CT imaging performed for clinical-care purposes.	OR will be determined in each subject 3 months following therapy using CT imaging performed for clinical-care purposes	No